The tick-over theory revisited: Is C3 a contact-activated protein?

Immunobiology

Volumn 217, Issue 11, 2012, Pages 1106-1110

  Nilsson, Bo ^a   Nilsson Ekdahl, Kristina ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Blood interfaces; C3; Contact activation; Surface interaction; Thioester; Tick over

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANAPHYLATOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; EPITOPE; HYDROGEN PEROXIDE; POLYSTYRENE; THIOESTER;

ABSORPTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONFORMATIONAL TRANSITION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; REVIEW; SURFACE PROPERTY; THROMBOCYTE ACTIVATION;

EID: 84866014027     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.008     Document Type: Review

References (42)

1. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
2. Andersson J., Nilsson Ekdahl K., Larsson R., Nilsson U.R., Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J. Immunol. 2002, 168:5786-5791.
3. Atkinson J.P., Farries T. Separation of self from non-self in the complement system. Immunol. Today 1987, 7-8:212-215.
4. Barak V., Selmi C., Schlesinger M., Blank M., Agmon-Levin N., Kalickman I., Gershwin M.E., Shoenfeld Y. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J. Autoimmun. 2009, 33:178-182.
5. Bexborn F., Andersson P.O., Chen H., Nilsson B., Nilsson Ekdahl K. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol. Immunol. 2008, 45:2370-2379.
6. Del Conde I., Cruz M.A., Zhang H., Lopez J.A., Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 2005, 201:871-879.
7. Fearon D.T., Austen K.F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:1683-1687.
8. Fearon D.T., Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 1975, 142:856-863.
9. Fearon D.T., Austen K.F., Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 1973, 138:1305-1313.
10. Fey G.H., Lundwall A., Wetsel R.A., Tack B.F., de Bruijn M.H., Domdey H. Nucleotide sequence of complementary DNA and derived amino acid sequence of murine complement protein C3. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1984, 306:333-344.
11. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
12. Hamad O.A., Nilsson P.H., Wouters D., Lambris J.D., Nilsson Ekdahl K., Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J. Immunol. 2010, 184:2686-2692.
13. Harboe M., Mollnes T.E. The alternative complement pathway revisited. J. Cell. Mol. Med. 2008, 12:1074-1084.
14. Janatova J., Lorenz P.E., Schechter A.N., Prahl J.W., Tack B.F. Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry 1980, 19:4471-4478.
15. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
16. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
17. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115-149.
18. Law S.K., Levine R.P. Interaction between the third complement protein and cell surface macromolecules. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:2701-2705.
19. Law S.K., Minich T.M., Levine R.P. Binding reaction between the third human complement protein and small molecules. Biochemistry 1981, 20:7457-7463.
20. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 1982, 129:184-189.
21. Nicol P.A., Lachmann P.J. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology 1973, 24:259-275.
22. Nilsson B., Bjelle A., Loof L., Nilsson U.R. Quantitation and antigenic characterization of bound C3 of circulating immune complexes in systemic lupus erythematosus, rheumatoid arthritis, and primary biliary cirrhosis. J. Clin. Immunol. 1987, 7:420-426.
23. Nilsson B., Nilsson Ekdahl K., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 2007, 44:82-94.
24. Nilsson B., Grossberger D., Nilsson Ekdahl K., Riegert P., Becherer D.J., Nilsson U.R., Lambris J.D. Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochem. J. 1992, 282(Pt. 3):715-721.
25. Nilsson B., Loof L., Nilsson U.R. Identification of a nonproteolytically activated C3 with CR 1-binding properties in sera from subjects with primary biliary cirrhosis. Int. Arch. Allergy Appl. Immunol. 1986, 80:312-319.
26. Nilsson B., Nilsson Ekdahl K., Avila D., Nilsson U.R., Lambris J.D. Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. Biochem. J. 1990, 268:55-61.
27. Nilsson B., Nilsson U.R. An assessment of the extent of antigenic analogy between physiologically bound C3 and C3 denatured by sodium dodecyl sulphate. Scand. J. Immunol. 1985, 22:703-710.
28. Nilsson B., Nilsson U.R. SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation. Immunol. Lett. 1986, 13:11-14.
29. Nilsson B., Svensson K.E., Borwell P., Nilsson U.R. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Mol. Immunol. 1987, 24:487-494.
30. Nilsson Ekdahl K., Nilsson B., Pekna M., Nilsson U.R. Generation of iC3 at the interface between blood and gas. Scand. J. Immunol. 1992, 35:85-91.
31. Nilsson U.R., Nilsson B. Analogous antigenic alterations elicited in C3 by physiologic binding and by denaturation in the presence of sodium dodecylsulfate. J. Immunol. 1982, 129:2594-2597.
32. Nilsson U.R., Storm K.E., Elwing H., Nilsson B. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol. Immunol. 1993, 30:211-219.
33. Pangburn M.K., Muller-Eberhard H.J. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 1980, 152:1102-1114.
34. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 1977, 146:257-270.
35. Pangburn M.K., Schreiber R.D., Müller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway, acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 1981, 154:856-867.
36. Peerschke E.I., Yin W., Grigg S.E., Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J. Thromb. Haemost. 2006, 4:2035-2042.
37. Pekna M., Hagman L., Halden E., Nilsson U.R., Nilsson B., Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann. Thorac. Surg. 1994, 58:421-424.
38. Pekna M., Nilsson L., Nilsson Ekdahl K., Nilsson U.R., Nilsson B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin. Exp. Immunol. 1993, 91:404-409.
39. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
40. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
41. Tack B.F., Harrison R.A., Janatova J., Thomas M.L., Prahl J.W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:5764-5768.
42. Whaley K., Thompson R.A. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum. Immunology 1978, 35:1045-1049.